4//SEC Filing
OTTO MICHAEL J. 4
Accession 0001209191-12-003881
CIK 0001301081other
Filed
Jan 16, 7:00 PM ET
Accepted
Jan 17, 4:58 PM ET
Size
21.8 KB
Accession
0001209191-12-003881
Insider Transaction Report
Form 4
Pharmasset IncVRUS
OTTO MICHAEL J.
Chief Scientific Officer
Transactions
- Disposition to Issuer
Stock Option (Right to Buy)
2012-01-12−12,142→ 0 totalExercise: $9.30Exp: 2018-10-29→ Common Stock (12,142 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2012-01-12−10,000→ 0 totalExercise: $2.01Exp: 2016-11-07→ Common Stock (10,000 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2012-01-12−27,442→ 0 totalExercise: $6.84Exp: 2017-10-10→ Common Stock (27,442 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2012-01-12−50,000→ 0 totalExercise: $16.17Exp: 2020-10-14→ Common Stock (50,000 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2012-01-12−0.67→ 0 totalExercise: $1.50Exp: 2014-08-10→ Common Stock (0.67 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2012-01-12−22,500→ 0 totalExercise: $10.83Exp: 2019-10-14→ Common Stock (22,500 underlying) - Disposition from Tender
Common Stock
2012-01-12$137.00/sh−14,378$1,969,786→ 0 total - Disposition to Issuer
Stock Option (Right to Buy)
2012-01-12−60,000→ 0 totalExercise: $83.52Exp: 2021-10-11→ Common Stock (60,000 underlying)
Footnotes (7)
- [F1]These options, which reflect the two-for-one stock split of the Issuer's common stock effective August 31, 2011 (the "Split") and which vested as to 25% on the first anniversary of the date of grant (August 10, 2004) and as to an additional 6.25% quarterly thereafter for the following three years, were cancelled pursuant to the Agreement and Plan of Merger between the Issuer and Gilead Sciences, Inc. (the "Merger Agreement") in exchange for a cash payment of $135.50 per share, representing the difference between the exercise price of the options and $137.00 per share.
- [F2]These options, which reflect the Split and which vested as to 25% on the first anniversary of the date of grant (November 7, 2006) and as to an additional 6.25% quarterly thereafter for the following three years, were cancelled pursuant to the Merger Agreement in exchange for a cash payment of $134.99 per share, representing the difference between the exercise price of the options and $137.00 per share.
- [F3]These options, which reflect the Split and which vested as to 25% on the first anniversary of the date of grant (October 10, 2007) and as to an additional 6.25% quarterly thereafter for the following three years, were cancelled pursuant to the Merger Agreement in exchange for a cash payment of $130.16 per share, representing the difference between the exercise price of the options and $137.00 per share.
- [F4]These options, which reflect the Split and which provided for vesting as to 25% on the first anniversary of the date of grant (October 29, 2008) and as to an additional 6.25% quarterly thereafter for the following three years, became fully vested and were cancelled pursuant to the Merger Agreement in exchange for a cash payment of $127.70 per share, representing the difference between the exercise price of the options and $137.00 per share.
- [F5]These options, which reflect the Split and which provided for vesting as to 25% on the first anniversary of the date of grant (October 14, 2009) and as to an additional 6.25% quarterly thereafter for the following three years, became fully vested and were cancelled pursuant to the Merger Agreement in exchange for a cash payment of $126.17 per share, representing the difference between the exercise price of the options and $137.00 per share.
- [F6]These options, which reflect the Split and which provided for vesting as to 25% on the first anniversary of the date of grant (October 14, 2010) and as to an additional 6.25% quarterly thereafter for the following three years, became fully vested and were cancelled pursuant to the Merger Agreement in exchange for a cash payment of $120.83 per share, representing the difference between the exercise price of the options and $137.00 per share.
- [F7]These options, which provided for vesting as to 25% on the first anniversary of the date of grant (October 11, 2011) and as to an additional 6.25% quarterly thereafter for the following three years, became fully vested and were cancelled pursuant to the Merger Agreement in exchange for a cash payment of $53.48 per share, representing the difference between the exercise price of the options and $137.00 per share.
Documents
Issuer
Pharmasset Inc
CIK 0001301081
Entity typeother
Related Parties
1- filerCIK 0001284621
Filing Metadata
- Form type
- 4
- Filed
- Jan 16, 7:00 PM ET
- Accepted
- Jan 17, 4:58 PM ET
- Size
- 21.8 KB